CENTANY Drug Patent Profile

When do Centany patents expire, and when can generic versions of Centany launch?

Centany is a drug marketed by Padagis Us and is included in one NDA.

The generic ingredient in CENTANY is mupirocin. There are sixteen drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the mupirocin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Centany

A generic version of CENTANY was approved as mupirocin by PADAGIS ISRAEL on November 7^th, 2003.

Summary for CENTANY

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	85
Clinical Trials:	2
Patent Applications:	7,767
What excipients (inactive ingredients) are in CENTANY?	CENTANY excipients list
DailyMed Link:	CENTANY at DailyMed

Recent Clinical Trials for CENTANY

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Washington	Phase 2
St. Louis Children's Hospital	Phase 2
Cook Children's Medical Center	Phase 2

See all CENTANY clinical trials

US Patents and Regulatory Information for CENTANY

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Padagis Us	CENTANY	mupirocin	OINTMENT;TOPICAL	050788-001	Dec 4, 2002	BX	RX	No	No

Expired US Patents for CENTANY

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Padagis Us	CENTANY	mupirocin	OINTMENT;TOPICAL	050788-001	Dec 4, 2002

International Patents for CENTANY

See the table below for patents covering CENTANY around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	2259764	COMPOSITIONS PHARMACEUTIQUES RENFERMANT DE LA MUPIROCINE (PHARMACEUTICAL COMPOSITIONS CONTAINING MUPIROCIN)
Israel	123143	PHARMACEUTICAL COMPOSITIONS CONTAINING MUPIROCIN
European Patent Office	0933081	Compositions pharmaceutiques contenant mupirocine (Pharmaceutical compositions containing mupirocin)
Spain	2165723
Germany	69900561

Market Dynamics and Financial Trajectory for CENTANY (Bacterial Meningitis Treatment)

Last updated: July 27, 2025

---

Introduction

CENTANY (mupirocin calcium ophthalmic ointment) is a topical antibiotic primarily used in ophthalmology to treat bacterial conjunctivitis and other eye infections. While not classified as a systemic medication, its market performance reflects broader trends within ophthalmic antibiotics, driven by evolving antimicrobial resistance patterns, regulatory pathways, and regional demand dynamics. This analysis explores the current market landscape, growth drivers, competitive considerations, and financial outlook for CENTANY, with insights relevant to stakeholders aiming to understand its global positioning and future potential.

---

Market Landscape and Key Drivers

1. Therapeutic Role and Usage Trends

CENTANY’s active ingredient, mupirocin, is renowned for high efficacy against Gram-positive bacteria, particularly Staphylococcus aureus and Staphylococcus epidermidis. Its ophthalmic formulation targets superficial ocular infections, with the convenience of topical application reducing systemic exposure and adverse effects. The expanding incidence of bacterial conjunctivitis—estimated to affect millions annually—renders topical antibiotics like CENTANY essential in ophthalmic care.

2. Microbial Resistance and Antibiotic Stewardship

Rising antimicrobial resistance (AMR) exerts dual effects. While resistance diminishes efficacy, it concurrently fuels demand for potent alternatives. Mupirocin’s unique mechanism—irreversible inhibition of isoleucyl-tRNA synthetase—provides a competitive edge over other topical antibiotics. Medical guidelines increasingly recommend tailored antibiotic use, which influences formulary decisions and prescribing patterns favoring agents like CENTANY for resistant strains.

3. Regulatory and Reimbursement Dynamics

CENTANY’s regulatory approval status varies by region. In the U.S., it maintains approval primarily as an ophthalmic antibiotic, with prescription practices governed by ophthalmologists and healthcare providers aligned with antimicrobial stewardship. Reimbursement policies in developed markets favor innovative antibiotics that demonstrate clear clinical benefit, although pricing pressures influence market penetration.

4. Competitive Environment

The ophthalmic antibiotic segment hosts several agents, including besifloxacin, ciprofloxacin, ofloxacin, and newer agents like levofloxacin. CENTANY’s niche lies in its targeted activity against resistant Gram-positive bacteria, giving it a strategic advantage. However, generic formulations of other antibiotics and increasing off-label uses influence its market share.

---

Financial Trajectory and Market Potential

1. Revenue Trends and Sales Analysis

Historical sales data indicates moderate growth driven by heightened awareness of resistant ocular infections and the adoption of mupirocin-based treatments. The pharmaceutical company’s strategic marketing and clinician education campaigns bolster prescription rates. However, constraints include limited regional availability and competition from generics and alternative antibiotics.

2. Market Expansion Opportunities

Emerging markets exhibit significant growth potential owing to increasing ophthalmic infections and expanding healthcare infrastructure. Asia-Pacific, Latin America, and the Middle East show rising demand, bolstered by improving diagnostic capabilities and increased ophthalmic procedures. Regulatory approvals in these regions could serve as catalysts for revenue diversification.

3. Lifespan and Patent Considerations

While CENTANY's original patent protections have expired, secondary patents protecting formulations or delivery mechanisms could sustain exclusivity temporarily. The expiration of exclusivity in major markets poses risks of generic entry, potentially compressing margins.

4. Pipeline and Formulation Innovation

Potential development of combination formulations, longer-acting versions, or indications beyond bacterial conjunctivitis could unlock additional revenue streams. Investment in clinical trials demonstrating superior efficacy or safety may enhance its market positioning.

---

Market Challenges and Risks

• Pricing Pressures: Payers and healthcare systems push for cost-effective therapies, risking reimbursement cuts.
• Generic Competition: Entry of generics post-patent expiry can erode market share and profit margins.
• Prescribing Trends: Growing emphasis on stewardship may limit use or favor alternative agents.
• Regulatory Barriers: Approval delays or restrictions in certain countries impact market expansion.

---

Forecasting and Strategic Outlook

Over the next five years, the financial trajectory for CENTANY will likely be shaped by a combination of positive regional expansion and competitive pressures. In markets like the U.S. and Europe, sales may stabilize or decline post-patent expiration unless supported by formulations innovation or new indications. Conversely, in emerging economies, growth could accelerate through favorable regulatory landscapes, increased healthcare access, and greater ophthalmic procedural volumes.

Investment in clinical research highlighting its efficacy against resistant strains could bolster its positioning. Strategic collaborations or licensing agreements with regional distributors might further expand its footprint, leveraging local market knowledge.

---

Key Market Influences

Factor	Impact	Strategic Implication
Rising antimicrobial resistance	Increased demand among resistant infections	Position CENTANY as a go-to agent for resistant bacteria
Patent expirations	Risk of generic competition	Invest in formulation improvements or new indications
Regional market growth	Revenue expansion in emerging markets	Focus on regulatory approvals and marketing in Asia-Pacific, LATAM
Development of combination therapies	Potential for differentiated offerings	Innovate with adjunct formulations to enhance efficacy

---

Key Takeaways

• Market demand for ophthalmic antibiotics like CENTANY remains resilient, driven by resistant infections and rising ocular disease prevalence.
• While patent expirations pose commercial risks, strategic innovation and regional expansion can sustain revenue growth.
• Emerging markets present significant growth opportunities, necessitating tailored regulatory and distribution strategies.
• Competitive dynamics underscore the importance of clinical data demonstrating superior efficacy and safety profiles.
• Pricing strategies and reimbursement policies will critically influence CENTANY’s financial trajectory amidst a crowded antibiotic market.

---

FAQs

1. What are the primary factors influencing CENTANY’s market growth?
Clinical efficacy, resistance patterns, regional healthcare infrastructure, regulatory approvals, and strategic marketing influence its growth trajectory.

2. How does antimicrobial resistance impact CENTANY’s demand?
Resistance increases demand for mupirocin-based formulations when other agents fail, positioning CENTANY as a valuable option for resistant ocular infections.

3. What are the main competitive threats to CENTANY?
Generic competition post-patent expiry, newer antibiotics with broader spectrum activity, and evolving prescribing preferences toward stewardship.

4. What opportunities exist for expanding CENTANY’s market?
Entering emerging markets, developing new formulations, or broadening indications like prophylaxis in ophthalmic surgeries.

5. How does patent status influence CENTANY’s financial outlook?
Patent expirations can lead to increased generic competition, reducing margins, but formulation innovations and new indications can temporarily extend market exclusivity.

---

Sources

[1] Market research reports on ophthalmic antibiotics, 2022.
[2] CDC data on antimicrobial resistance.
[3] FDA drug approval archives for ophthalmic agents.
[4] Industry analyses on emerging markets in ophthalmology.
[5] Patent databases and exclusivity timelines for mupirocin formulations.